[go: up one dir, main page]

DK3372229T3 - Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom - Google Patents

Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom Download PDF

Info

Publication number
DK3372229T3
DK3372229T3 DK18169211.2T DK18169211T DK3372229T3 DK 3372229 T3 DK3372229 T3 DK 3372229T3 DK 18169211 T DK18169211 T DK 18169211T DK 3372229 T3 DK3372229 T3 DK 3372229T3
Authority
DK
Denmark
Prior art keywords
angelman
syndrome
procedures
treatment
tonic inhibition
Prior art date
Application number
DK18169211.2T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Application granted granted Critical
Publication of DK3372229T3 publication Critical patent/DK3372229T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK18169211.2T 2014-06-06 2015-06-03 Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom DK3372229T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia

Publications (1)

Publication Number Publication Date
DK3372229T3 true DK3372229T3 (da) 2021-06-14

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15803364.7T DK3151832T3 (da) 2014-06-06 2015-06-03 Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed
DK18169211.2T DK3372229T3 (da) 2014-06-06 2015-06-03 Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15803364.7T DK3151832T3 (da) 2014-06-06 2015-06-03 Fremgangsmåder til øgning af tonisk hæmning og behandling af sekundær søvnløshed

Country Status (20)

Country Link
US (11) US20150352085A1 (da)
EP (3) EP3372229B1 (da)
JP (4) JP2017516868A (da)
AR (1) AR100772A1 (da)
AU (4) AU2015269667B2 (da)
CA (1) CA2950845C (da)
CY (2) CY1124366T1 (da)
DK (2) DK3151832T3 (da)
ES (2) ES2876350T3 (da)
HR (2) HRP20210901T1 (da)
HU (2) HUE055400T2 (da)
IL (2) IL249287B (da)
LT (2) LT3151832T (da)
MX (2) MX380868B (da)
PL (2) PL3372229T3 (da)
PT (2) PT3372229T (da)
RS (2) RS62006B1 (da)
SI (2) SI3372229T1 (da)
SM (2) SMT202100340T1 (da)
WO (1) WO2015187851A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
US10080898B2 (en) * 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
MX2019001669A (es) 2016-08-11 2019-09-27 Ovid Therapeutics Inc Metodos y composiciones para el tratamiento de trastornos epilepticos.
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
CN113395962A (zh) * 2018-11-21 2021-09-14 Certego治疗公司 加波沙朵用于降低自杀风险和快速缓解抑郁症
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US20210015760A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
AU2020405060A1 (en) 2019-12-18 2022-06-09 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
AU2021275863A1 (en) 2020-05-20 2023-02-02 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤
US20240285562A1 (en) * 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
MXPA06011325A (es) 2004-04-02 2006-12-15 Lundbeck & Co As H Tratamiento de la funcion respiratoria alterada con gaboxadol.
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
WO2009064928A1 (en) 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
CA2732636A1 (en) * 2008-09-01 2009-05-07 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of pat1 or oat
PL3372229T3 (pl) 2014-06-06 2021-10-04 Ovid Therapeutics, Inc. Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
MX391708B (es) * 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
ES2876350T3 (es) 2021-11-12
AU2020217342A1 (en) 2020-08-27
US20230051859A1 (en) 2023-02-16
US9339495B2 (en) 2016-05-17
HRP20210901T1 (hr) 2021-09-17
IL268960A (en) 2019-10-31
HRP20210902T1 (hr) 2021-09-17
AU2024202604A1 (en) 2024-05-09
US20180015076A1 (en) 2018-01-18
JP2017516868A (ja) 2017-06-22
US20160228418A1 (en) 2016-08-11
US9801864B2 (en) 2017-10-31
AU2020217342B2 (en) 2021-10-07
US20150352085A1 (en) 2015-12-10
IL249287B (en) 2021-03-25
CY1124366T1 (el) 2022-07-22
JP2021178836A (ja) 2021-11-18
US20170273956A1 (en) 2017-09-28
US20160038469A1 (en) 2016-02-11
AR100772A1 (es) 2016-11-02
MX2016016136A (es) 2017-07-05
CA2950845A1 (en) 2015-12-10
SMT202100340T1 (it) 2021-07-12
CY1124368T1 (el) 2022-07-22
CA2950845C (en) 2023-04-25
SI3372229T1 (sl) 2021-09-30
AU2015269667A1 (en) 2016-12-22
US11278529B2 (en) 2022-03-22
PL3151832T3 (pl) 2021-10-25
US9744159B2 (en) 2017-08-29
LT3372229T (lt) 2021-07-12
DK3151832T3 (da) 2021-06-14
US20220016091A1 (en) 2022-01-20
EP3151832A1 (en) 2017-04-12
US20250025448A1 (en) 2025-01-23
JP2023123442A (ja) 2023-09-05
AU2015269667B2 (en) 2020-07-30
US20180303805A1 (en) 2018-10-25
AU2022200085A1 (en) 2022-02-03
US20170071917A1 (en) 2017-03-16
HUE055400T2 (hu) 2021-11-29
PL3372229T3 (pl) 2021-10-04
MX380868B (es) 2025-03-12
RS62007B1 (sr) 2021-07-30
EP3372229A1 (en) 2018-09-12
JP2020063264A (ja) 2020-04-23
US20170087133A1 (en) 2017-03-30
EP3795156A1 (en) 2021-03-24
RS62006B1 (sr) 2021-07-30
LT3151832T (lt) 2021-07-12
IL249287A0 (en) 2017-02-28
HUE055155T2 (hu) 2021-11-29
EP3151832A4 (en) 2018-01-17
IL268960B (en) 2021-05-31
EP3151832B1 (en) 2021-03-24
SMT202100343T1 (it) 2021-07-12
MX391502B (es) 2025-03-21
PT3372229T (pt) 2021-06-17
EP3372229B1 (en) 2021-03-24
ES2875742T3 (es) 2021-11-11
WO2015187851A1 (en) 2015-12-10
US9446028B2 (en) 2016-09-20
PT3151832T (pt) 2021-06-15
MX2020012404A (es) 2022-04-11
SI3151832T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
DK3372229T3 (da) Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom
IL286888A (en) Use of pridopidine to treat depression or anxiety
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3364993T3 (da) Fremgangsmåder til behandling af angelman syndrom
IL253463A0 (en) Binding-triggered transcriptional switches and methods of use thereof
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PL3402888T3 (pl) Środki i sposoby leczenia hbv
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3204497T3 (da) Terapeutisk hæmning af lactatdehydrogenase og midler dertil
DK3238707T3 (da) Sammensætninger og fremgangsmåder til behandling af intestinal hyperpermeabilitet
PT3319612T (pt) Oxisteróis e métodos de utilização dos mesmos
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3209696T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3107902T3 (da) Forbindelser og fremgangsmåder til at hæmme fascin
DK3828203T3 (da) Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning
PL3204030T3 (pl) Terapia skojarzona zakażenia hbv i hdv
DK3512506T3 (da) Anvendelse af pridopidin til behandling af retts syndrom
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3237621T5 (da) Varianter af human alpha-galactosidase
DK2961420T3 (da) Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom